News

Primary hypoparathyroidism may go undiagnosed until a secondary condition, such as dengue, worsens levels of blood calcium, a case report suggests. The report, “Dengue fever manifesting with tetany as the first presentation of primary hypoparathyroidism: a case report,” was published in the journal BMC Research Notes. Dengue…

A plasma gel scaffold, easily injected and capable of delivering cells that produce and release the parathyroid hormone (PTH), could be a potential new treatment for hypoparathyroidism patients, a study reports. The study, “Feasibility of autologous plasma gel for tonsil-derived stem cell therapeutics in hypoparathyroidism,” was conducted by Korean…

Patients with small papillary thyroid cancers should not undergo a total thyroidectomy, but should instead be under active surveillance to monitor the cancer, or remove only a portion of the thyroid. This could avoid the patient developing hypoparathyroidism, according to a new perspective article. The article, “Saving…

With the increasing use of parathyroid hormone therapy in patients with hypoparathyroidism, physicians need to closely monitor urinary citrate levels which, if too low, may result in calcium deposits and kidney stones, according to researchers. Their study, “Hypocitraturia is an Untoward Side Effect of Synthetic Human Parathyroid Hormone…

Diagnoses other than epilepsy, including hypoparathyroidism, should be considered when a patient arrives at the emergency room with seizures, according to a new case study. The report, “Hypoparathyroidism Causing Seizures: When Epilepsy Does Not Fit,” was published in Case Reports in Medicine. Adult-onset seizures are not an uncommon…

Long-term treatment with the human recombinant parathyroid hormone (rhPTH) in patients with hypoparathyrodism causes significant and sustained changes in bone remodeling and structural changes to the bone, according to researchers. Their study, “The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry,” was published in the Journal of…

A new, small, orally available compound has the potential to regulate abnormal calcium levels often seen in patients with hypoparathyroidism, according to preclinical research. The study, “Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small-Molecule for Treatment of Hypoparathyroidism,” was published…

The U.S. Food and Drug Administration has granted orphan drug designation to TransCon PTH, an investigative therapy by Ascendis Pharma to treat hypoparathyroidism. Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH), resulting in low calcium and elevated phosphate levels in the blood. TransCon…

Treatment with the injectable parathyroid hormone Natpara slows the decline in kidney function in patients with chronic hypoparathyroidism, according to recent clinical trial data. Natpara, developed by Shire, is a recombinant human parathyroid hormone (rhPTH[1-84]) approved as an add-on to the conventional treatment of chronic hypoparathyroidism with calcium and activated…

Atypical kidney lesions in adult patients may be caused by a mutation associated with a rare type of  hypoparathyroidism, according to a case report. The study,“Unusual Proliferative Glomerulonephritis in a Patient Diagnosed to Have Hypoparathyroidism, Sensorineural Deafness, and Renal Dysplasia (HDR) Syndrome with…